2026 ICD-10-CM Diagnosis Code T39.8X5SAdverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, sequela
T39.8X5S is a billable ICD-10-CM diagnosis code for adverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, sequela. The 7th character S marks it as a sequela code, which reports a problem that remains after the original condition has resolved. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 922 through 923. The code is not accepted as a principal diagnosis by the Medicare Code Editor and exempt from POA reporting. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Poisoning/toxic effect/adverse effects/underdosing, sequela.
Code Identity
Code Classification
Code EditsBilling
Medicare Code Editor checks that affect claim validity for T39.8X5S.
Present on Admission (POA)Billing
T39.8X5S is exempt from POA reporting on inpatient claims to general acute care hospitals. Review other POA exempt codes.
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Adverse reaction to pyrabital
- Bilateral retinopathy caused by pentosan polysulfate
- Disorder of retina caused by pentosan polysulfate
- Ketorolac adverse reaction
- Left retinopathy caused by pentosan polysulfate
- Meptazinol adverse reaction
- Nefopam adverse reaction
- Pentosan polysulfate sodium maculopathy
- Right retinopathy caused by pentosan polysulfate
- Toxic maculopathy
Coding GuidelinesGuidance
When coding an adverse effect of a drug that has been correctly prescribed and properly administered, assign the appropriate code for the nature of the adverse effect followed by the appropriate code for the adverse effect of the drug.
The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of nonopioid analgesics, antipyretics and antirheumatics (T39). Use the following options for the applicable episode of care:
- A - initial encounter
- D - subsequent encounter
- S - sequela
Source: ICD-10-CM Official Guidelines for Coding and Reporting, FY 2026, published by CMS and the National Center for Health Statistics.
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Clonixin
anti-inflammatory analgesic.Glafenine
an anthranilic acid derivative with analgesic properties used for the relief of all types of pain.Jamaica
an island in the greater antilles in the west indies. its capital is kingston. it was discovered in 1494 by columbus and was a spanish colony 1509-1655 until captured by the english. its flourishing slave trade was abolished in the 19th century. it was a british colony 1655-1958 and a territory of the west indies federation 1958-62. it achieved full independence in 1962. the name is from the arawak xaymaca, rich in springs or land of springs. (from webster's new geographical dictionary, 1988, p564 & room, brewer's dictionary of names, 1992, p267)Smilax
a plant genus of the family smilacaceae. members contain smiglasides (phenylpropanoid glycosides) and steroidal saponins. commercially it is sometimes adulterated with hemidesmus, which would affect experimental results. drinks called sarsaparilla and root beer have been prepared from the smilaz ornata (jamaican sarsaparilla) and sassafras.Ketorolac
a pyrrolizine carboxylic acid derivative structurally related to indomethacin. it is an nsaid and is used principally for its analgesic activity. (from martindale the extra pharmacopoeia, 31st ed)Ketorolac Tromethamine
a pyrrolizine carboxylic acid derivative structurally related to indomethacin. it is a non-steroidal anti-inflammatory agent used for analgesia for postoperative pain and inhibits cyclooxygenase activity.Meptazinol
a narcotic antagonist with analgesic properties. it is used for the control of moderate to severe pain.Nefopam
non-narcotic analgesic chemically similar to orphenadrine. its mechanism of action is unclear. it is used for the relief of acute and chronic pain. (from martindale, the extra pharmacopoeia, 30th ed, p26)Phenazopyridine
a local anesthetic that has been used in urinary tract disorders. its use is limited by problems with toxicity (primarily blood disorders) and potential carcinogenicity.Sumatriptan
a serotonin agonist that acts selectively at 5ht1 receptors. it is used in the treatment of migraine disorders.
Table of Drugs and ChemicalsClinical
Substances in the Table of Drugs and Chemicals that reference this code family. Always confirm in the Tabular List before coding.
Patient EducationClinical
Drug Reactions
Most of the time, medicines make our lives better. They reduce aches and pains, fight infections, and control problems such as high blood pressure or diabetes. But medicines can also cause unwanted reactions, such as drug interactions, side effects, and allergies.
The full article covers:
- What is a drug interaction?
- What are side effects?
- What are drug allergies?
- How can I stay safe when taking medicines?
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert T39.8X5S to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About T39.8X5SOverview
Is T39.8X5S a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report adverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, sequela on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What does the 7th character S in T39.8X5S mean?
The final character S makes this a sequela code: it reports a lingering problem that remains after the adverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified itself has resolved, not the original event.
What MS-DRG does T39.8X5S group to?
On inpatient claims, adverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, sequela maps to MS-DRG 922, 923, with relative weights from 1.0177 to 1.7494 depending on complications. Higher weights mean higher Medicare reimbursement.
Can T39.8X5S be a principal diagnosis?
No. The Medicare Code Editor rejects this code as a principal diagnosis because adverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, sequela describes a circumstance that influences health status rather than a current illness. Report it as a secondary diagnosis.
Is T39.8X5S exempt from POA reporting?
Yes. CMS lists this code among those exempt from present on admission reporting, so hospitals do not assign a POA indicator for adverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, sequela on inpatient claims.
Footnotes
[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.
